Last 12 months
Inside the activity.
15 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 8 | 0 |
| Oct 2026 | 6 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2023 Filed Sep 5, 2023 15:54 UTC |
Olds DonaldDirector
|
PurchaseCommon Shares | 381 | $2.05 | $781.05 |
DisclosureSEC source: 0001062993-23-017516 · form4.xml · nonDerivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381 Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:26 UTC |
Kohli PrashantChief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 208,334 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014994 · form4.xml · derivative · entry 1 Kohli Prashant · CIK 0001946739 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,334 Underlying: Class A Common Shares · 208,334 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 16:37 UTC |
Derby MichaelDirector
|
GrantStock Options (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-015000 · form4.xml · derivative · entry 1 Derby Michael · CIK 0001809613 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Shares · 12,500 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 16:36 UTC |
Olds DonaldDirector
|
GrantStock Options (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014998 · form4.xml · derivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Shares · 12,500 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:34 UTC |
Macdonald R. LochChief Medical Officer
|
GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014997 · form4.xml · derivative · entry 1 Macdonald R. Loch · CIK 0001653008 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Class A Common Shares · 60,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:36 UTC |
Kavuru VimalDirector
|
GrantStock Options (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014999 · form4.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Shares · 12,500 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:32 UTC |
D'Andrea CarrieVP Clinical Operations
|
GrantStock Options (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014996 · form4.xml · derivative · entry 1 D'Andrea Carrie · CIK 0001977969 · VP Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Class A Common Shares · 42,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:28 UTC |
Kumar AmreshVP Program Management
|
GrantStock Options (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014995 · form4.xml · derivative · entry 1 Kumar Amresh · CIK 0001978220 · VP Program Management 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Class A Common Shares · 42,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 16:18 UTC |
Derby MichaelDirector
|
GrantStock Options (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001171843-22-006332 · ownership.xml · derivative · entry 1 Derby Michael · CIK 0001809613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Class A Common Shares · 85,000 shares Expires 2032-09-28 F1 · derivative.exercise_price: Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 16:20 UTC |
Olds DonaldDirector
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001171843-22-006334 · ownership.xml · derivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Shares · 45,000 shares Expires 2032-09-28 F1 · derivative.exercise_price: Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:21 UTC |
Kavuru VimalDirector
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001171843-22-006335 · ownership.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Shares · 45,000 shares Expires 2032-09-28 F1 · derivative.exercise_price: Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:19 UTC |
Canan JohnDirector
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001171843-22-006333 · ownership.xml · derivative · entry 1 Canan John · CIK 0001374366 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Shares · 45,000 shares Expires 2032-09-28 F1 · derivative.exercise_price: Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:34 UTC |
Lemieux PierreCOO, Canada & CSO
|
GrantStock Options (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001171843-22-004517 · ownership.xml · derivative · entry 1 Lemieux Pierre · CIK 0001807098 · COO, Canada & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Class A Common Shares · 165,000 shares Expires 2032-06-22 F1 · derivative.exercise_price: Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:34 UTC |
Kottayil GeorgeCOO, US
|
Grant06/22/2022 · Derivative | 50,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001171843-22-004516 · ownership.xml · derivative · entry 1 Kottayil George · CIK 0001895357 · COO, US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Shares · 50,000 shares Expires 2032-06-22 F1 · derivative.exercise_price: Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:33 UTC |
D'Alvise JanelleDirector · PRESIDENT & CEO
|
GrantStock Options (Right to Buy) · Derivative | 560,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001171843-22-004514 · ownership.xml · derivative · entry 1 D'Alvise Janelle · CIK 0001807412 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,000 Underlying: Class A Common Shares · 560,000 shares Expires 2032-06-22 F1 · derivative.exercise_price: Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 20:34 UTC |
Ford Brian D.CHIEF FINANCIAL OFFICER
|
GrantStock Options (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001171843-22-004515 · ownership.xml · derivative · entry 1 Ford Brian D. · CIK 0001825758 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Class A Common Shares · 165,000 shares Expires 2032-06-22 F1 · derivative.exercise_price: Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:20 UTC |
Lemieux PierreCOO, Canada & CSO
|
GrantStock Options (Right to Buy) · Derivative | 287,900 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008010 · ownership.xml · derivative · entry 1 Lemieux Pierre · CIK 0001807098 · COO, Canada & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,900 Underlying: Class A Common Shares · 287,900 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:19 UTC |
HASELTINE WILLIAM ADirector
|
GrantStock Options (Right to Buy) · Derivative | 42,100 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008008 · ownership.xml · derivative · entry 1 HASELTINE WILLIAM A · CIK 0000938807 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,100 Underlying: Class A Common Shares · 42,100 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:21 UTC |
Olds DonaldDirector
|
GrantStock Options (Right to Buy) · Derivative | 42,100 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008011 · ownership.xml · derivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,100 Underlying: Class A Common Shares · 42,100 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:18 UTC |
D'Alvise JanelleDirector · PRESIDENT & CEO
|
GrantStock Options (Right to Buy) · Derivative | 655,500 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008006 · ownership.xml · derivative · entry 1 D'Alvise Janelle · CIK 0001807412 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,500 Underlying: Class A Common Shares · 655,500 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:17 UTC |
Carter Roderick NoelDirector
|
GrantStock Options (Right to Buy) · Derivative | 42,100 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008005 · ownership.xml · derivative · entry 1 Carter Roderick Noel · CIK 0001807558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,100 Underlying: Class A Common Shares · 42,100 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:20 UTC |
Kavuru VimalDirector
|
GrantStock Options (Right to Buy) · Derivative | 42,100 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008009 · ownership.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,100 Underlying: Class A Common Shares · 42,100 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:18 UTC |
Ford Brian D.CHIEF FINANCIAL OFFICER
|
GrantStock Options (Right to Buy) · Derivative | 287,900 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008007 · ownership.xml · derivative · entry 1 Ford Brian D. · CIK 0001825758 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,900 Underlying: Class A Common Shares · 287,900 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:16 UTC |
Canan JohnDirector
|
GrantStock Options (Right to Buy) · Derivative | 42,100 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008004 · ownership.xml · derivative · entry 1 Canan John · CIK 0001374366 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,100 Underlying: Class A Common Shares · 42,100 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.